Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients (1998)
    Springer
    Annals of oncology 9 (1998), S. 1351-1353 
    Details
    ISSN: 1569-8041
    Keywords: gemcitabine ; mycosis fungoides ; peripheral T-cell lymphoma ; skin involvement
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: Gemcitabine is a novel nucleoside analogue which has shown promising results in most solid tumors; like the arabinosylcytosine analogue, gemcitabine may be an active drug in lymphoproliferative malignancies. We tested it in pretreated peripheral T-cell lymphoma patients with isolated skin involvement. Patients and methods: We performed a phase II study with the drug in 13 pretreated patients with peripheral T-cell lymphoma, five of whom had advanced-stage mycosis fungoides (MF), and eight peripheral T-cell lymphoma unspecified (PTCLU). Patients were treated on days 1, 8, and 15 of a 28-day schedule at the dosage of 1200 mg/m2 for a total of three courses. Results: Of the 13 patients, one achieved complete response (CR) and eight achieved partial responses (PR); the remaining four showed no benefit from the treatment. Among the responders, one CR and four PR were documented in the PTCLU patients and four PR in MF patients. Treatment was well tolerated; hematologic toxicity was mild and no nausea/vomiting or organ toxicity was recorded. Conclusions: In view of its significant activity and its modest toxicity profile, the role of gemcitabine deserves further evaluation in the management of pretreated patients with peripheral T-cell lymphoma.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008409601731
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification (1997)
    Springer
    Annals of oncology 8 (1997), S. 583-592 
    Details
    ISSN: 1569-8041
    Keywords: anaplastic large cell lymphoma ; classification ; clinics ; histology ; immunohistochemistry ; peripheral T-cell lymphoma
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: One hundred sixty-eight peripheral T-cell lymphomas (PTCLs)were reviewed according to the Revised European–American Lymphoma (R.E.A.L.)Classification. Patients and methods: The cases, originally diagnosed on the basis of theUpdated Kiel Classification (UKC), were all provided with histologicalpreparations, immunophenotype, clinical information, and follow-up data. Theslides were reclassified by five observers, who integrated the R.E.A.Lcriteria with cell size measurements. The prognostic value of clinical andpathologic findings was assessed by univariate and multivariate analysis. Results: The R.E.A.L. Classification was reproducibly applied by all of theobservers. Clinically, anaplastic large cell lymphomas (ALCLs) differed fromthe remaining PTCLs by mean age (29.5 vs. 52.9 years), bulky disease(52.3% vs. 11.3%; P = 0.000), mediastinal mass (52.7% vs.32%; P = 0.004), and disease-free survival (68.0% vs.38.2%; P = 0.0001). Although each histological type displayed specificclinical aspects, PTCLs other than ALCL were basically characterised by a poorclinical outcome which was not influenced by the UKC malignancy grade. Atmultivariate analysis, the risk of a lower complete remission rate was relatedto bulky disease (P = 0.001), histologic group (non-ALCL) (P = 0.01), andadvanced stage (III–IV) (P = 0.0002). Conclusions: The present study supports the classification of T-celllymphomas proposed by the R.E.A.L. scheme.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008200307625
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Nongastrointestinal mucosa-associated lymphoid tissue (MALT) lymphomas: Clinical and therapeutic features of 24 localized patients (1997)
    Springer
    Annals of oncology 8 (1997), S. 883-886 
    Details
    ISSN: 1569-8041
    Keywords: α-interferon ; low-grade MALT lymphoma ; nongastrointestinal ; radiotherapy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: Peripheral B-cell lymphoma of the marginal zone (MALT, low-grade), presenting as localized, extranodal disease, usually affects the elderly. The gastrointestinal tract is the most frequently involved extranodal location, representing 70% of all MALT lymphomas. Recently, numerous other extranodal sites involved by MALT lymphomas have also been described. Patients and methods: From January 1990 to October 1995, 24 patients with untreated nongastrointestinal low-grade MALT lymphoma were submitted to treatments ranging from the local approach of radiotherapy and local α-interferon (α-IFN) administration to chemotherapy. The tumours were located in the lung (seven cases), conjunctiva (four cases), lachrymal gland and orbital soft tissue (four cases), salivary glands (three cases), skin (three cases), breast (two cases)' and thyroid (one case). All patients had low-grade stage IE tumours. Results: Chemotherapy was administered in 11 patients (six with lung, three with salivary gland, one with breast, and one with thyroid locations); radiation therapy was employed in seven patients (three with lachrymal gland, three with skin, and one with breast locations); local α-IFN administration was administered in five patients (four with conjunctival, and one with lachrymal gland sites); and surgery was employed in one patient with a lung tumour. All patients achieved complete remissions; three local recurrences and two relapses in other sites were observed. The global five-year survival rate was 100% with a relapse-free survival rate of 79%. Conclusions: These data confirm the significant efficacy of different therapeutic approaches to specific sites inbes obtaining a good remission rate for nongastrointestinal localized low-grade MALT lymphomas.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008278725106
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Fludarabine–mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma (1997)
    Springer
    Annals of oncology 8 (1997), S. 379-383 
    Details
    ISSN: 1569-8041
    Keywords: fludarabine ; mitoxantrone ; non-Hodgkin's lymphoma ; response rate
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: The promising results of fludarabine (FLU) in chroniclymphocytic leukemia have prompted its extensive evaluation in low-gradenon-Hodgkin's lymphoma (LG-NHL). Its different mechanisms of action make FLUan attractive partner for combination with other cytostatic agents. Patients and methods: We used a three-drug combination of FLU (25mg/m2 i.v. on days one to three), mitoxantrone (10mg/m2 i.v. on day one) and prednisone (40 mg per os on daysone to five) (FMP) to treat 48 patients with recurrent LG-NHL. Results: Of the 48 patients, 17 (35%) achieved complete responses(CR), 23 (48%) partial responses, while the remaining 8 (17%)showed no benefit from the treatment. The risk of lower CR rate wassignificantly correlated with the presence of advanced stage (IV) (P = 0.01),the number of previous regimens (〉3) (P = 0.006), and the follicularhistologic subtype (P = 0.02). The major toxic effects observed wereneutropenia and infections; there was only one fatality, due to drug-relatedside effects. Conclusions: These data confirm the significant efficacy of the FMPfludarabine-mitoxantrone combination regimen in obtaining a good remissionrate with moderate toxicity in a particular subset of recurrent LG-NHL.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008228709612
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    The role of positron emission tomography (PET) in the management of lymphoma patients (1999)
    Springer
    Annals of oncology 10 (1999), S. 1181-1184 
    Details
    ISSN: 1569-8041
    Keywords: abdominal mass ; aggressive NHL ; CT scan ; HD ; PET
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: Treatment of both Hodgkin's disease (HD) and aggressive non-Hodgkin's lymphoma (NHL) with abdominal presentation at the time of diagnosis is often followed by detection of residual masses by computed tomography (CT). However, CT is usually unable to disciminate between residual tumor and fibrosis/necrosis. We investigated the ability of fluorine-18 fluorodeoxyglucose positron emission tomography (PET) to differentiate between residual active tumor tissue and fibrosis. Patients and methods: Forty-four patients with HD or aggressive NHL presenting abdominal involvement (41% with bulky mass) were studied with CT and PET at the end of chemotherapy ± radiation therapy. Results: After treatment, seven patients had negative PET and CT, and none of them relapsed. The remaining 37 patients all had positive CT (abnormalities ≤10%). All of the 13 who also had positive PET relapsed (100%). By contrast, there was only 1 (4%) relapse among the 24 patients who were positive at CT but negative at PET. The two-year actuarial relapse-free survival rate was 95% for those with negative PET compared with 0% for positive PET patients (P 〈 0.000000). Conclusions: In lymphoma patients with abdominal masses who present CT positivity at restaging, PET should be considered the noninvasive imaging modality of choice for differentiating early recurrences or residual disease from fibrosis.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008327127033
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    T-cell prolymphocytic leukaemia: Does the expression of CD8+ phenotype justify the identification of a new subtype? (1999)
    Springer
    Annals of oncology 10 (1999), S. 649-653 
    Details
    ISSN: 1569-8041
    Keywords: cytogenetics ; peripheral T-cell lymphoma ; phenotype ; T-cell chronic lymphocytic leukaemia ; T-cell prolymphocytic leukaemia
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract T-cell chronic lymphocytic leukaemia (T-CLL) has recently been reclassified under the heading of T-cell prolymphocytic leukaemia (T-PLL) because of its unfavourable clinical course, independently of the morphologic features. This rare neoplasm usually shows CD4+/CD8− phenotype. Herein we report on two cases of T-PLL with CD8 expression that correspond to a possible variant of the disease first proposed by Hui et al. in 1987. These cases presented with malignant cells showing immunophenotypic features that can be easily identified and distinguished from other peripheral T-cell leukemias. However, the total number of cases studied is inadequate for defining a discrete clinico-pathologic entity with characteristic clinical features and cytogenetical abnormalities. An international collaboration in which tissue from similar cases is referred to a central pathologist for immunophenotyping and cytogenetical study, and clinical data are centrally compiled, may assist in defining this rare malady as a discrete clinico-pathologic entity.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008349422735
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...